Stocks TelegraphStocks Telegraph
Stock Ideas

MLTX Stock Performance and Key Statistics

NASDAQ : MLTX

MoonLake Immunotherapeutics

$22.16
2.95+15.36%
At Close 4:00 PM
74.22
BESG ScoreESG Rating

stock performance chart

MLTX Fundamental Analysis

Based on recent data, MoonLake Immunotherapeutics (MLTX) shows an Average True Range (ATR) of 1.05 and an Enterprise Value of 2.2B. Its average trading volume over the past 3 months is 1.02M, indicating liquidity. These fundamental metrics provide insight into MLTX's underlying financial health and market activity.

ATR1.05
Enterprise Value2.2B
Avg Vol (3 Months)1.02M
Avg Vol (10 Days)1.48M

MLTX Technical Analysis Indicators

MoonLake Immunotherapeutics (MLTX) technical indicators as of June 23, 2026: the SMA 20 is 6.32%, SMA 50 at 14.08%, and SMA 200 at -42.56%. The RSI 14 value is 58.23, suggesting its current momentum. These technical analysis signals help assess MLTX's price trends and potential future movements.

SMA 206.32%
SMA 5014.08%
SMA 200-42.56%
RSI 1458.23

MLTX Stock Performance Overview

MoonLake Immunotherapeutics (MLTX) stock performance overview as of June 23, 2026: The 52-week high is $62.75 (currently -71.82% below), and the 52-week low is $5.95 (currently 197.14% above). Over the past year, MLTX's performance is -60.62%, compared to the S&P 500's 10.67% change.

52-Week High62.75
52-Week High Chg-71.82%
52-Week Low5.95
52-Week Low Chg+197.14%
S&P 500 52-Week Chg10.67%

MoonLake Immunotherapeutics (MLTX) Historical Stock Performance

According to market data, MoonLake Immunotherapeutics (MLTX) stock's recent performance metrics show that over the last month, MLTX is 17.06%, with a Year-to-Date (YTD) performance of 23.9%. Over the past year, the stock has seen a -60.62% change. These figures summarize MLTX's price movements across various periods, reflecting its historical returns.

Period1 Week1 MonthQuarterHalf Year1 YearYTD
High23.2923.2923.2923.2962.7523.29
Low18.2316.5315.7611.065.9511.06
Performance-9.73%+17.06%+79.06%-69.52%-60.62%+23.90%

Industry Analysis and Valuation

According to current financial data, MLTX stock's P/E (TTM) ratio is -5.68, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for MLTX, including P/S (N/A), P/B (6.19), and P/FCF (-7.24), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.

ValuationMLTXSector MedianIndustry AvgS&P 500
P/E (TTM)-5.68-1.22-5.0232.59
P/S (TTM)N/A3.69462.045.98
P/B (TTM)6.190.0512.185
P/FCF (TTM)-7.24-11.65-908.5628.32

Frequently Asked Questions

How is MLTX price-to-earnings ratio currently?
MLTX has a current P/E ratio of -5.68
How are MLTX's price-to-sale and price-to-book ratios?
The MLTX stock has a trailing twelve month price-to sales (P/S) ratio of N/A while its price-to-book (P/B) value is 6.19.
Is MoonLake Immunotherapeutics's price-to-cashflow ratio high or low?
MLTX's price-to-free-cashflow (P/FCF) ratio is -7.24, an indicator that is currently being trending upward.
What's current simple moving average (SMA) for MLTX?
Based on MLTX's recent bid, its distance from 20 days simple moving average is 6.32%. It is 14.08% apart from 50 days simple moving average, and it is -42.56% apart from 200 days simple moving average.
What is the 52-week price range for MLTX?
The 52-week high for MLTX is $62.75 which is -71.82% away from the current price level whereas the distance of that from the 52-week low of $5.95 stands at 197.14%.
An overview of MLTX's stock performance: how did it fare?
The performance of MLTX stock was not encouraging with most of its significant price indicators in green. MoonLake Immunotherapeutics(NASDAQ: MLTX) shares have moved upward +15.36% or $2.95 in the latest trading session and have gained 23.9% year-to-date (YTD). The stock has lost nearly -60.62% over the past year. After moving 79.06% over the trailing 3-month period, the stock is -69.52% lower in the 6-month period. Looking at its performance over the shorter term, it'slost -9.73% a week and 17.06% a month.
What is MLTX's 14-day relative strength index (RSI)?
The current 14-day RSI for MLTX stock is 58.23. Investors and traders alike rely on the relative strength index, or RSI, as an oscillating indicator. In terms of values, the RSI operates within a range ranging from 0 to 100. A rising RSI line indicates strength in the shares. As the RSI line falls, the opposite occurs. It is possible to examine different time periods when using the RSI indicator. Shorter time frames can cause the RSI to be more volatile. Most traders pay close attention to the marks between 30 and 70 on the RSI scale. When the stock price moves over 70, it is often considered to be an indicator of overbought conditions. Dropping below 30 indicates oversold territory. These levels are often used by traders to forecast stock price reversals.
For MLTX, what is the average true range (ATR) for the past two weeks?
ATR stands for Average True Range, which may be useful when traders or investors are assessing technical inventory. Currently, MoonLake Immunotherapeutics (MLTX) has a 14-day ATR of 1.05.
What is MLTX's current enterprise value?
After closing at $19.21 with 73.62M of its shares outstanding, the current enterprise value of MLTX is roughly 2.2B.
Over the past year, how has the stock price of MLTX changed?
MoonLake Immunotherapeutics (NASDAQ: MLTX) is down -60.62% when it comes to the percentage price change over the past 52-weeks. The percentage price change came less than that of broader S&P 500 index that came at a fall of 10.67%. MLTX stock price is also up 23.9% on its value in year-to-date trading.
What is the average trading volume for MLTX shares?
The number outstanding shares of MLTX is 73.62M, and of these 86.84% shares are freely available for trading. On average, MLTX stock has traded 1.48M shares per day for the past 10 days. A total of 3.38M shares changed hands during the last trading session with the average session volume of 1M shares.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph